INDBInternet News Database 2.5 Updated 2 min ago · 370 sources Show or hide images Light or dark

Results for “Omalizumab May Ease Alpha-Gal”

Health
1 source

Who is covering this

MedscapeCenter
Truth score 38
Centre 100%100%
MedscapeCenter

Omalizumab May Ease Alpha-Gal Reactions

In a 64-patient study, no patients require epinephrine for food-related reactions while receiving omalizumab.

Lean: Center Fact-focusedFactuality: Mostly factualCountry: United StatesFunding: CorporateOwner: Independent
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
Independent100%
Avg reliability65
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 38 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 65 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Science
1 source

Who is covering this

Google NewsCenter
Truth score 41
Centre 100%100%
Google NewsCenter

From tick bite to meat allergy: Scientists investigate the mystery link

From tick bite to meat allergy: Scientists investigate the mystery link The Washington Post For alpha-gal patients, allergy drug could cut the severity of reactions to red meat NBC News Existing allergy drug shows promise for people...

Lean: Center Fact-focusedFactuality: HighCountry: United StatesFunding: Corporate
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
Google News100%
Avg reliability75
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 41 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 75 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like
Health
1 source

Who is covering this

MedpagetodayCenter
Truth score 38
Centre 100%100%
MedpagetodayCenter

Omalizumab Linked With Anaphylaxis Elimination in Meat Allergy

(MedPage Today) -- For patients with alpha-gal syndrome who had severe allergic reactions to red meat despite avoidance, treatment with omalizumab (Xolair) appeared to eliminate anaphylaxis risk in one case series. Whereas 53% of 64...

Lean: Center Fact-focusedFactuality: Mostly factualCountry: United StatesFunding: CorporateOwner: Independent
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
Independent100%
Avg reliability65
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 38 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 65 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Like